Tag Archives: Amicus Therapeutics

September, 2018

August, 2018

July, 2016

  • 8 July

    Amicus Acquires MiaMed Gaining Rare Disease Preclinical Program

    CRANBURY, N.J., July 06, 2016 (GLOBE NEWSWIRE) — Amicus Therapeutics, Inc. (Nasdaq:FOLD), a biotechnology company at the forefront of rare and orphan diseases, has expanded its biologics pipeline with a new preclinical program for cyclin-dependent kinase-like 5 (CDKL5) deficiency, a rare and devastating genetic neurological disease for which there is …

March, 2015